

## What is Gene Expression Classifier (GEC) Testing?

- Gene expression classifier (GEC) testing can be performed on prostate biopsies to provide additional information about your cancer in a personalized report. It is performed on tissue from your prior biopsy.
- There are three different types of GEC testing: Decifer, Oncotype Dx GPS, and Prolaris that look at disease aggressiveness and likelihood of it spreading to other parts of the body. However, the impact this information has on patient care is still being understood.



- For patients in this study, your doctor will review with you the askMUSIC report, an online tool that provides information on treatment decisions made by other men in Michigan with similar characteristics.

For more information, please visit:  
[www.musicUrology.com/GMAJOR](http://www.musicUrology.com/GMAJOR)



For additional information regarding this informational brochure, please contact us at:

**MUSIC Coordinating Center**  
2800 Plymouth Rd.  
Building 16  
Ann Arbor, MI 48109

(855) 456 - 2035  
[www.musicurology.com](http://www.musicurology.com)

Copyright 2020.  
For questions about the Michigan Urological Surgery Improvement Collaborative, please contact us at [musicurology@umich.edu](mailto:musicurology@umich.edu)

MUSIC is sponsored by:



**Blue Cross  
Blue Shield**  
of Michigan

A nonprofit corporation and independent licensee  
of the Blue Cross and Blue Shield Association



**GMAJOR**  
Genomics in Michigan to AdJust  
Outcomes in Prostate Cancer



**Improving Prostate  
Cancer Care in Michigan:  
now and in the future**

## What is MUSIC and MROQC?



Your doctor is a member of the:

- **Michigan Urological Surgery Improvement Collaborative (MUSIC)**, focused on improving urologic care for patients in Michigan.
- or
- **Michigan Radiation Oncology Quality Consortium (MROQC)**, focused on improving radiation treatment for patients in Michigan.

**MUSIC** and **MROQC** have come together to improve care for prostate cancer patients now and in the future.

## What is G-MAJOR?

The **Genomics in Michigan to AdJust Outcomes in Prostate Cancer (G-MAJOR)** research project is a randomized clinical trial (study that randomly assigns participants to one arm to fairly understand outcomes) that aims to assess if information from gene expression classifier (GEC) testing is helpful for both patients and their doctors in the management of care for newly diagnosed prostate cancer patients.

## Who participants in G-MAJOR?

Patients who have been newly diagnosed with prostate cancer, undergone a prostate biopsy in the past 9 months, and:

- Age 18 years or older
- PSA <20 ng/mL
- Gleason score 3+3=6 prostate cancer with more than 2 biopsy cores positive or Gleason score 3+4=7 prostate cancer.

*Participation is voluntary and confidential.*




PSA: blood sample test measuring the amount of prostate-specific antigen protein being produced by the prostate.

Gleason Score: determined by comparing abnormal cells to healthy cells from biopsy tissue and how likely they are to grow and spread.

## How do I participate?

- ✓ After signing a written informed consent:
  - You will be randomly assigned to one of the trial pathways (see below).
  - A sample of your prostate biopsy tissue will be sent to a processing lab by your study team.



- ✓ After you select a treatment:
  - Your doctor will encourage you to participate in the **MUSIC Patient Reported Outcomes (PRO)** program to better understand your health and function before and after surgery.
  - You will receive a questionnaire to complete at enrollment and at 1\*, 3, 6, 12, 24, and 36 months after treatment or diagnosis.

*\*PRO 1 month questionnaire sent only to patients with email access.*